Globeimmune Net Cash Flow 2013-2016 | GBIM
Globeimmune net cash flow from 2013 to 2016. Net cash flow can be defined as the total change in cash for the company over the given period.
Globeimmune Annual Net Cash Flow
(Millions of US $) |
| 2015 |
$-7 |
| 2014 |
$11 |
| 2013 |
$4 |
| 2012 |
$-13 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
GlobeImmune, Inc. is a biopharmaceutical company. It is focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen (R) platform. The Company's products under development includes GI-5005, a product for the treatment of chronic hepatitis C infection; and GI-4000 for pancreas, non-small cell lung, colorectal, and other cancers. GlobeImmune, Inc. is based in Louisville, Colorado.
|
